Based on the available information, there is some potential for Cosentyx (secukinumab) to affect the efficacy of live vaccines. Secukinumab is a human monoclonal antibody that selectively neutralizes interleukin-17A, which is involved in the inflammatory response in various diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to a study published in the Journal of Dermatological Treatment, immunomodulatory therapies such as biologics, including secukinumab, can affect the immune response to vaccines [2]. Specifically, the study found that patients treated with biologics had a reduced response to vaccines, including live vaccines. However, the study did not specifically investigate the impact of secukinumab on live vaccine efficacy.

The Cosentyx website also acknowledges the potential impact of the drug on the immune system, stating that "Cosentyx affects your immune system and can lower your ability to fight infections" [3]. However, the website does not provide specific information on the impact of Cosentyx on live vaccine efficacy.

Therefore, while there is some evidence to suggest that Cosentyx may affect the efficacy of live vaccines, more research is needed to fully understand the impact of the drug on vaccine response. It is recommended that patients consult with their healthcare provider before receiving any vaccinations while on Cosentyx therapy.

Sources:

* <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>
* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767096/>
* <https://www.cosentyx.com/all/covid19>